Hims & Hers Health, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Hims & Hers (HIMS) stock rose 9.1% in after-hours trading to $29.34, adding $550 million in market value. The price movement may indicate a shift in trader sentiment, but its sustainability will be tested at the market open.
Regencell Bioscience (RGC) rose 35% to $11 before retreating below $10, with a market cap of $4B. It reported a net loss of $11.7M. Hims & Hers (HIMS) gained 5%, nearing $30. Both stocks face technical and fundamental risks.
Hims & Hers Health (HIMS) stock fell 52% in 12 months, despite 40% sales growth in Q2 2026. Growth drivers include expanded weight loss products, Eucalyptus acquisition, and international revenue. Gross margin fell to 64%, and the company reported a net loss of $86 million. The FTC filed a complaint, and the company faces a securities class action.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning HIMS (Hims & Hers Health, Inc.). Coverage has skewed bullish: 6 bullish, 2 neutral, and 1 bearish.
Recent HIMS coverage spans financial news, market movers and earnings.
In the last 30 days, HIMS insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($2.3M). The most active reporter was Boughton Soleil, Chief Legal Officer, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
After-hours strength suggests bullish repricing, but the article frames the next decision as whether the move holds at the regular-session open.
Momentum recovery attempt faces technical resistance, with the key risk being failure to break out from the moving-average range.
Hims & Hers faces margin pressure from a shifting sales mix and regulatory risk from the FTC case, which may keep the stock under pressure.
The Australia platform launch is likely to be viewed as incremental growth and customer acquisition expansion, but near-term financial impact is uncertain.
The stock experienced a sharp intraday rally.
AlphAI scores every news story that mentions HIMS with an AI model for sentiment and relevance, and aggregates insider trades from Hims & Hers Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Hims & Hers (HIMS) stock rose 9.1% in after-hours trading to $29.34, adding $550 million in market value. The price movement may indicate a shift in trader sentiment, but its sustainability will be tested at the market open.
2 min readRegencell Bioscience (RGC) rose 35% to $11 before retreating below $10, with a market cap of $4B. It reported a net loss of $11.7M. Hims & Hers (HIMS) gained 5%, nearing $30. Both stocks face technical and fundamental risks.
5 min readHims & Hers Health (HIMS) stock fell 52% in 12 months, despite 40% sales growth in Q2 2026. Growth drivers include expanded weight loss products, Eucalyptus acquisition, and international revenue. Gross margin fell to 64%, and the company reported a net loss of $86 million. The FTC filed a complaint, and the company faces a securities class action.
2 min readHims & Hers Health launched its Hers platform in Australia, rebranding Juniper. The platform offers treatments for hair regrowth, menopause, and weight management, with 24/7 care support. The company cited internal data on healthcare avoidance among Australian women. Australia's telehealth sector is projected to grow to $2.56B by 2034. Gus Wood and Dr. Matt Vickers lead the Australian operations.
3 min readHims & Hers Health (HIMS) shares rose 10% on Friday to $30.92, rebounding from a 5% decline the prior session. Trading volume reached 15.92 million shares, 1.65 times the average.
1 min readHims & Hers Health (HIMS) rose 7.36% to $30.13 on news of potential peptide regulation changes. The company plans to offer peptides by 2026. Analysts have mixed views, with Citi targeting $25 (17% downside) and Truist at $32. Q3 earnings on Nov 9, 2026, will be key.
2 min readSpaceX (SPCX) agreed to acquire $8 billion in wireless spectrum, adding up to 14 MHz of nationwide low-band capacity for Starlink Mobile. Analysts see this as a major step toward becoming a standalone mobile provider, with Evercore maintaining a $230 price target and JPMorgan estimating potential wireless spectrum auction spending of up to $53 billion. SpaceX has a Moderate Buy consensus rating with an average price target of $216.21, implying 34% upside potential.
1 min readHims & Hers Health (HIMS) stock fell 46% over the past year despite 40% revenue growth in Q2 2026. The company reported a $68M cash burn, citing expansion in its weight loss business and legal costs. While liquidity is sufficient for now, further cash burn could lead to dilution or increased debt. Investors should monitor free cash flow in Q3 2026.
2 min readHims & Hers Health (HIMS) appointed Jon Franklin as chief accounting officer, succeeding Irene Becklund. Franklin previously held roles at Rivian (RIVN) and PwC. The company did not disclose details about Becklund's departure. Franklin's experience includes corporate finance and audit work, aligning with HIMS's expansion plans.
2 min readTruist reiterated a Hold rating on Hims and Hers (HIMS) with a $32 price target, citing proprietary card data showing a 16% decline in GLP-1 billings in September. The stock trades at $29.54, with InvestingPro suggesting it may be overvalued. KeyBanc maintained a Sector Weight rating, noting AI-driven healthcare improvements. The company faces challenges from Visa's Acquirer Monitoring Program due to credit card disputes.
1 min read
